Adjuvant osimertinib in EGFR mutant early stage NSCLC: Does HRQOL influence decisions?

The ADAURA adjuvant randomized trial demonstrated that osimertinib prolonged DFS. It has now been reported that health related quality of life (HRQOL) was not adversely affected by adjuvant osimertinib. Does this mean that adjuvant osimertinib should now be standard as we await survival results?